Chardan analyst Daniil Gataulin raised the firm’s price target on Zura Bio (ZURA) to $12 from $11 and keeps a Buy rating on the shares following the Q3 report. The firm says tibulizumab’s Phase 2b in systemic sclerosis is on track for a Q4 initiation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZURA: